About NFlection Therapeutics

NFlection Therapeutics is developing first-in-class MEK inhibitors for the topical treatment of neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. The company aims to provide targeted therapies that address the unmet medical needs of patients suffering from these RAS-mediated disorders.

<problem> Neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks are disorders driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. These conditions often lack targeted therapies, resulting in unmet medical needs for affected patients. </problem> <solution> NFlection Therapeutics develops first-in-class MEK (mitogen-activated protein kinase kinase) inhibitors designed for topical treatment of neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks. By targeting the Ras/Raf/MEK/ERK pathway, the company aims to provide novel therapies that directly address the underlying mechanisms of these RAS-mediated disorders. The topical application allows for targeted drug delivery, potentially minimizing systemic side effects. NFlection's approach focuses on developing treatments that can improve patient outcomes and quality of life. </solution> <features> - First-in-class MEK inhibitors specifically designed for topical application. - Targeted treatment of neurofibromatosis type 1. - Targeted treatment of immunosuppressant-mediated squamous cell carcinoma. - Targeted treatment of congenital birthmarks such as keratinocytic epidermal nevi and nevi sebacei. - Aims to inhibit the Ras/Raf/MEK/ERK pathway. </features> <target_audience> The primary target audience includes patients suffering from neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks, as well as the physicians who treat these conditions. </target_audience>

What does NFlection Therapeutics do?

Where is NFlection Therapeutics located?

NFlection Therapeutics is based in Boston, United States.

How much funding has NFlection Therapeutics raised?

NFlection Therapeutics has raised 20000000.

Location

Boston, United States

Funding

20000000

Employees

10 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

NFlection Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

nflectionrx.com 300+

Crunchbase

Boston, United States

Funding

Estimated Funding

$20M+

Team (10+)

No team information available.

Company Description

Problem

Neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks are disorders driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. These conditions often lack targeted therapies, resulting in unmet medical needs for affected patients.

Solution

NFlection Therapeutics develops first-in-class MEK (mitogen-activated protein kinase kinase) inhibitors designed for topical treatment of neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks. By targeting the Ras/Raf/MEK/ERK pathway, the company aims to provide novel therapies that directly address the underlying mechanisms of these RAS-mediated disorders. The topical application allows for targeted drug delivery, potentially minimizing systemic side effects. NFlection's approach focuses on developing treatments that can improve patient outcomes and quality of life.

Features

First-in-class MEK inhibitors specifically designed for topical application.

Targeted treatment of neurofibromatosis type 1.

Targeted treatment of immunosuppressant-mediated squamous cell carcinoma.

Targeted treatment of congenital birthmarks such as keratinocytic epidermal nevi and nevi sebacei.

Aims to inhibit the Ras/Raf/MEK/ERK pathway.

Target Audience

The primary target audience includes patients suffering from neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks, as well as the physicians who treat these conditions.